Fate Therapeutics: Q3 Earnings Snapshot

SAN DIEGO (AP) — SAN DIEGO (AP) — Fate Therapeutics Inc. (FATE) on Tuesday reported a loss of $47.7 million in its third quarter.

On a per-share basis, the San Diego-based company said it had a loss of 40 cents.

The results exceeded Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share.

The clinical-stage biotech company that develops stem cell treatments posted revenue of $3.1 million in the period, which also beat Street forecasts. Five analysts surveyed by Zacks expected $880,000.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FATE at https://www.zacks.com/ap/FATE

Copyright © 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.

Federal News Network Logo
Log in to your WTOP account for notifications and alerts customized for you.

Sign up